XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 33,609 $ 50,482
Accounts receivable, net 147 481
Inventories 3,155 3,155
Prepaid expenses and other current assets 3,326 31,542
Current assets held for sale 108,292 110,849
Total current assets 148,529 196,509
Other assets 1,121 1,405
Long-term assets held for sale 15,563 16,611
Total assets 165,213 214,525
Current liabilities:    
Accounts payable 7,282 5,064
Accrued and other current liabilities 35,324 62,035
Deferred revenue 22,509 27,290
Current liabilities held for sale 8,275 38,917
Total current liabilities 73,390 133,306
Product development obligations 17,799 17,012
Deferred revenue, net of current 115,347 114,708
Senior secured term loan facilities, non-current 73,419 73,092
Liability related to sale of future revenues, non-current 59,168 58,864
Other long-term liabilities 830 822
Long-term liabilities held for sale 189 356
Total liabilities 340,142 398,160
Commitments and Contingencies
Redeemable non-controlling interests 21,480 21,480
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024
Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2025 and December 31, 2024; 101,044 and 100,917 shares issued outstanding at March 31, 2025 and December 31, 2024 1,010 1,009
Additional paid-in capital 1,671,388 1,668,620
Accumulated other comprehensive loss (4,434) (5,732)
Accumulated deficit (1,884,860) (1,889,499)
Total stockholders' deficit attributable to FibroGen (216,896) (225,602)
Nonredeemable non-controlling interests 20,487 20,487
Total deficit (196,409) (205,115)
Total liabilities, redeemable non-controlling interests and deficit $ 165,213 $ 214,525